Temporal control of CAR expression by a tumor-targeting albumin adapter and logic gating enhances CAR-T cell therapy for solid tumors.

Temporally gated MANAGE CAR-T cells using a FITC-sensing synNotch receptor reduce exhaustion and preserve stem-like phenotypes versus constitutive CAR-T in solid-tumor in vivo models.

• Why it matters: Solid tumors limit CAR-T efficacy, and both tonic and persistent antigen-driven CAR signaling are linked to T cell exhaustion, motivating strategies that restrict and pulse CAR expression.
• What they did: The study built modular artificial- and natural-antigen-gated CAR-T cells where FITC-modified tumor-targeting priming adapters control CAR expression timing in vivo, then compared them to constitutive and endogenous-antigen-gated synNotch CAR-T.
• The result: Temporally tuned MANAGE CAR-T cells show substantially reduced exhaustion and better stem-like preservation, and albumin-based adapter–primed MANAGE CAR-T achieved complete responses without overt toxicity in immunologically “cold” breast cancer and glioblastoma models.

AI summary of the abstract · may contain errors · not medical advice · read the paper.